Steroid News and Research

RSS

First study to explore the use of biofeedback as a complementary treatment to asthma medication

For the estimated 20.3 million adults and 6.3 million children in the U.S. who suffer from asthma, the primary treatment is the use of medications to help reduce the underlying inflammation in the airways.

22 Feb 2005

FDA approves new smallpox vaccination

The U.S. Food and Drug Administration (FDA) has approved Vaccinia Immune Globulin Intravenous (VIGIV) - the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination.

20 Feb 2005

New detection system to test athletes for performance-enhancing drugs

Scientists at The University of Nottingham are leading the field in developing a new detection system that could be used to test athletes for performance-enhancing drugs.

16 Feb 2005

Sex hormone progesterone metabolite allopregnanolone reduces stress

A steroid hormone released during the metabolism of progesterone, the female sex hormone, reduces the brain's response to stress, according to research in rats by scientists at Emory University School of Medicine, the Yerkes National Primate Research Center and Atlanta's Center for Behavioral Neuroscience.

9 Feb 2005

Racial differences may play a significant role in determining a patient's response to asthma medications

A new study in the February issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), shows that asthmatic and nonasthmatic African-Americans required higher doses of glucocorticoids to suppress lymphocytes, which play an important role in airway inflammation.

7 Feb 2005

Why some men develop aggressive prostate cancer that becomes resistant to hormone-withdrawal therapy

Researchers found that certain mutations in a protein called the androgen receptor cause advanced and invasive prostate cancer when put into otherwise healthy mice. The androgen receptor's normal function is to control growth of the prostate gland in response to cues from male hormones called androgens, which have long been thought to stimulate prostate tumors.

26 Jan 2005

Launch date announced for Abraxane to treat metastatic breast cancer

American Pharmaceutical Partners announced today that February 8, 2005 is the launch date of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Abraxane will be marketed by the national sales force of Abraxis Oncology, APP's proprietary sales and marketing division.

25 Jan 2005

Use of anti-inflammatory steroids for traumatic head injuries may actually increase the risk of death

The common use of anti-inflammatory steroids for traumatic head injuries like those from car crashes may actually increase the risk of death, according to a new review of studies about the treatment.

24 Jan 2005

Over-eating at an early age may stay well into adulthood

Melbourne researchers have found that over-eating at a very young age can have a long-lasting effect on the body and in particular seems to enhance the production of hormones made in fat and involved in metabolism.

24 Jan 2005

Doctor report cards not always clear when comparing quality of care

When choosing a doctor based on increasingly popular “doctor report cards,” patients should be aware that the areas in which physicians are graded are not always clear-cut, according to researchers from the Johns Hopkins Bloomberg School of Public Health and School of Medicine.

19 Jan 2005

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.

9 Jan 2005

Promising new evidence for the optimal use of biologic therapies for rheumatoid arthritis

A major cause of pain and disability, rheumatoid arthritis (RA) is also potentially the most treatable form of chronic arthritis. Researchers, doctors, and patients agree that a group of drugs called disease-modifying antirheumatic drugs (DMARDs) can effectively reduce joint pain and stiffness.

7 Jan 2005

Night-time splinting can effectively improve discomfort from early symptoms of carpal tunnel syndrome

After a long day on the job, tired minds and sore feet look forward to a long night of rejuvenating rest. A new study finds that nocturnal rest can do a world of good for your hands and wrists too, especially if you are one of the millions of American workers who are just beginning to feel the common pain and discomfort linked to carpal tunnel syndrome.

5 Jan 2005

Minimally invasive surgery to alleviate the pain and pressure of sinusitis is a safe

Minimally invasive surgery to alleviate the pain and pressure of sinusitis is a safe, effective therapy for geriatric patients who can't be helped by medication alone, according to new research.

3 Jan 2005

Teen concerns about inhalants and painkiller use

According to the Department of Health and Human Services, results from the annual Monitoring the Future (MTF) survey indicate an almost 7 percent decline of any illicit drug use in the past month by 8th, 10th, and 12th graders combined from 2003 to 2004.

21 Dec 2004

5000 year old system of medicine provides pain relief for people with osteoarthritis of the knee

A 5000 year old system of medicine, acupuncture provides pain relief and improves function for people with osteoarthritis of the knee and serves as an effective complement to standard care.

20 Dec 2004

Advice for patients who have been taking Celebrex or Bextra

The recent announcement that Celebrex, a popular pain drug in the same family as Vioxx, has been found to pose an increased risk of heart problems is bound to leave many pain patients stunned, confused and worried.

20 Dec 2004

Lupus drug may also be useful in treating psoriasis

A new drug candidate previously shown to reduce harmful side effects of the autoimmune disease lupus also may be useful in treating psoriasis.

13 Dec 2004

Novel anti-rejection protocol should allow major improvement efficacy and quality of life after intestinal and multivisceral transplants

Transplant researchers at the University of Pittsburgh's Thomas E. Starzl Transplantation Institute have dramatically improved intestinal transplant graft survival, and reduced rejection and infection rates by successfully using a novel immunosuppression minimization protocol, thus improving patients' overall quality of life and avoiding the use of several anti-rejection drugs, which can cause serious infections and major complications.